nature portfolio

Corresponding author(s):	Elizabeth A. Campbell, Seth A. Darst
Last updated by author(s):	May 19, 2022

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

\sim				
⟨.	tっ	÷ι	ct	ICS
٠,	_		^ 1	11 >

101	an statistical analyses, commit that the following items are present in the figure regend, that regend, main text, or methods section.
n/a	Confirmed
	\square The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
	🔀 A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
\boxtimes	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
\boxtimes	A description of all covariates tested
\boxtimes	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
\boxtimes	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
\boxtimes	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
\boxtimes	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
\boxtimes	Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i>), indicating how they were calculated
	Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.

Software and code

Policy information about availability of computer code

Data collection

Leginon (ref. 36) SerialEM (ref. 43)

Data analysis

Structural biology software was accessed through the SBGrid consortium (ref. 35). MotionCor2 (ref. 37)

CryoSPARC v3.1.0 (ref. 38) RELION 3.1 (ref. 40) Bsoft package (ref. 20) 3DFSC package (ref. 41)

ChimeraX (ref. 44) Phenix (ref. 42)

Thermo Xcalibur Qual Browser v.4.2.47

UniDec v.4.2.0 (ref. 47, 48) Molprobity (ref. 49)

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

Data availability. All unique/stable reagents generated in this study are available without restriction from the corresponding authors, Seth A. Darst (darst@rockefeller.edu) and E.A. Campbell (campbee@rockefeller.edu). The cryo-EM density maps and atomic coordinates have been deposited in the EMDataBank and Protein Data Bank as follows: S1 RDV-TP (EMD-26639, PDB 7UO4), S2 ATP (EMD-26641, PDB 7UO7), S3 UTP (EMD-26642, PDB 7UO9), S4 GTP (EMD-26645, 7UOB), S5_CTP (EMD-26646, PDB 7UOE).

Human research participants

Policy information about <u>studies in</u>	nvolving human research participants and Sex and Gender in Research.
Reporting on sex and gender	n/a
Population characteristics	n/a
Recruitment	n/a
Ethics oversight	n/a
Note that full information on the appr	oval of the study protocol must also be provided in the manuscript.
Field-specific re	porting

Blinding

Please select the o	ne below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.				
X Life sciences	fe sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences				
For a reference copy of	the document with all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>				
Life scier	nces study design				
All studies must dis	sclose on these points even when the disclosure is negative.				
Sample size	We did not perform power analysis for sample size calculation.				
Data evolucions	We excluded some particles from our gree EM data based on their 2 D projections and 2D reconstruction due to their change not recombling				

Replication

Experiments were performed 2-3 biological replicates, each with three technical replicates (see figure legends for detail). Biological replicates were performed on different days within 2 weeks.

Randomization Randomization does not apply to our study as it does not involve clinical data.

Blinding does not apply in our study as it does not involve clinical data.

our complex such as contaminations and/or low-resolution features.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems Methods n/a Involved in the study n/a Involved in the study ☑ Antibodies ☑ ChIP-seq ☑ Eukaryotic cell lines ☑ Flow cytometry ☑ Palaeontology and archaeology ☑ MRI-based neuroimaging ☑ Animals and other organisms ☑ Clinical data

Dual use research of concern